Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

Colleen M. Niswender, Kari A. Johnson, C. David Weaver, Carrie K. Jones, Zixiu Xiang, Qingwei Luo, Alice L. Rodriguez, Joy E. Marlo, Tomas de Paulis, Analisa D. Thompson, Emily L. Days, Tasha Nalywajko, Cheryl A. Austin, Michael Baxter Williams, Jennifer E. Ayala, Richard Williams, Craig W. Lindsley and P. Jeffrey Conn
Molecular Pharmacology November 2008, 74 (5) 1345-1358; DOI: https://doi.org/10.1124/mol.108.049551
Colleen M. Niswender
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kari A. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. David Weaver
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carrie K. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zixiu Xiang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingwei Luo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice L. Rodriguez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joy E. Marlo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas de Paulis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Analisa D. Thompson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily L. Days
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tasha Nalywajko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl A. Austin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Baxter Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer E. Ayala
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig W. Lindsley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Jeffrey Conn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Parkinson's disease (PD) is caused by the death of dopamine neurons in the basal ganglia and results in motor symptoms such as tremor and bradykinesia. Activation of metabotropic glutamate receptor 4 (mGluR4) has been shown to modulate neurotransmission in the basal ganglia and results in antiparkinsonian effects in rodent PD models. N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) is a positive allosteric modulator (PAM) of mGluR4 that has been used to further validate the role of mGluR4 in PD, but the compound suffers from a lack of selectivity, relatively low potency, and poor solubility. Via high-throughput screening, we discovered more than 400 novel PAMs of mGluR4. Compounds derived from a novel chemical scaffold were characterized in vitro at both rat and human mGluR4 using two distinct assays of mGluR4 function. The lead compound was approximately 8-fold more potent than PHCCC, enhanced the potency of glutamate at mGluR4 by 8-fold, and did not show any significant potentiator or antagonist activity at other mGluR subtypes. Resolution of the regioisomers of the lead revealed that the cis regioisomer, (±)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic acid (VU0155041), contained the majority of the mGluR4 PAM activity and also exhibited partial agonist activity at mGluR4 at a site that was distinct from the glutamate binding site, suggesting that this compound is a mixed allosteric agonist/PAM of mGluR4. VU0155041 was soluble in an aqueous vehicle, and intracerebroventricular administration of 31 to 316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. These exciting results provide continued support for mGluR4 as a therapeutic target in PD.

Footnotes

  • This work was supported by National Institutes of Health grants NS053536 (to C.M.N.), NS051342, NS031373, MH074953, and NS048334 (to P.J.C.), the Dystonia Research Foundation (to Z.X.), the Alpha Foundation (to P.J.C.), and the Michael J. Fox Foundation (to P.J.C.).

  • C.M.N. and K.A.J. contributed equally to this work.

  • ABBREVIATIONS: mGluR, metabotropic glutamate receptor; GPCR, G protein-coupled receptor; HTS, high-throughput screening; GIRK, G-protein-regulated inwardly rectifying potassium channel; HEK, human embryonic kidney; DMSO, dimethyl sulfoxide; PHCCC, N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide; MPEP, 2-methyl-6-(phenylethynyl)pyridine hydrochloride; LY341495, (2S)-2-amino-2-[(1S,2S)-2-carboxyclycloprop-1-yl]-3-(xanth-9-yl) propanoic acid; Ro25-6981, (αR,βS)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol; NMDA, N-methyl-d-asparate; VU0003423, 2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid; VU0155040, (±)-trans-2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid; VU0155041, (±)-cis-2-(3,5-dicholorphenylcarbamoyl)-cyclohexanecarboxylic acid; l-AP4, l-(+)-amino-4-phosphonobutyric acid; TVC, third ventricle cannulated; PD, Parkinson's disease; PAM, positive allosteric modulator; icv, intracerebroventricular; CHO, Chinese hamster ovary; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; HEK, human embryonic kidney; FDSS, Functional Drug Screening System; BHK, baby hamster kidney; GTPγS, guanosine 5′-O-(3-thio)triphosphate; ACSF, artificial cerebrospinal fluid; NMDAR, N-methyl-d-aspartate receptor; GPe, globus pallidus external segment; SNr, substantia nigra pars reticulata; QX-314, N-(2,6-dimethylphenylcarbamoylmethyl)triethylammonium bromide; SIB-1893, 2-methyl-6-(2-phenylethenyl)pyridine.

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

    • Received June 6, 2008.
    • Accepted July 29, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 74 (5)
Molecular Pharmacology
Vol. 74, Issue 5
1 Nov 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

Colleen M. Niswender, Kari A. Johnson, C. David Weaver, Carrie K. Jones, Zixiu Xiang, Qingwei Luo, Alice L. Rodriguez, Joy E. Marlo, Tomas de Paulis, Analisa D. Thompson, Emily L. Days, Tasha Nalywajko, Cheryl A. Austin, Michael Baxter Williams, Jennifer E. Ayala, Richard Williams, Craig W. Lindsley and P. Jeffrey Conn
Molecular Pharmacology November 1, 2008, 74 (5) 1345-1358; DOI: https://doi.org/10.1124/mol.108.049551

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

Colleen M. Niswender, Kari A. Johnson, C. David Weaver, Carrie K. Jones, Zixiu Xiang, Qingwei Luo, Alice L. Rodriguez, Joy E. Marlo, Tomas de Paulis, Analisa D. Thompson, Emily L. Days, Tasha Nalywajko, Cheryl A. Austin, Michael Baxter Williams, Jennifer E. Ayala, Richard Williams, Craig W. Lindsley and P. Jeffrey Conn
Molecular Pharmacology November 1, 2008, 74 (5) 1345-1358; DOI: https://doi.org/10.1124/mol.108.049551
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of Celecoxib targets by label-free TPP
  • Editing TOP2α Intron 19 5′ SS Circumvents Drug Resistance
  • CTS Bias
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics